Kejin Zhou is a serial biotechnology platform developer, propelled by a steadfast commitment to realizing a cancer-free future. With demonstrated proficiency in Organic Chemistry, Polymer Physics, Nanotechnology, Drug Delivery, Biology, Cancer Biology, Immunology, Pharmacology, and Pharmaceutical Science, Kejin has played a pivotal role in the development of two platform technologies licensed to VC-backed biotech companies—OncoNano Medicine and Recode Therapeutics. The fight against cancer holds deeply personal significance for Kejin. Having experienced the anguish of witnessing his young niece's suffering and eventual loss to cancer, he harbors an unwavering determination to spare others from similar pain. Motivated by this trauma, Kejin founded Reinvigoron TheraTech, where the primary mission is to eradicate cancer. At Reinvigoron, the focus lies on inventing safe, life-saving, and scalable therapies, particularly targeting patients battling advanced metastatic solid cancer.